A R Nissenson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi The human nephron filter: toward a continuously functioning, implantable artificial nephron system
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Blood Purif 23:269-74. 2005
  2. ncbi Continuously functioning artificial nephron system: the promise of nanotechnology
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, California 90095, USA
    Hemodial Int 9:210-7. 2005
  3. ncbi Restructuring the ESRD payment system in the United States
    Allen R Nissenson
    David Geffen School of Medicine and UCLA Medical Center, Los Angeles, California, USA
    Kidney Int 66:466-76. 2004
  4. ncbi Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients
    Allen R Nissenson
    University of California at Los Angeles Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 40:110-8. 2002
  5. ncbi Septicemia in patients with ESRD is associated with decreased hematocrit and increased use of erythropoietin
    Allen R Nissenson
    David Geffen School of Medicine, University of California Los Angeles, 200 UCLA Medical Plaza, Suite 565 57, Los Angeles, CA 90095, USA
    Clin J Am Soc Nephrol 1:505-10. 2006
  6. ncbi The National Anaemia Action Council, Inc.: the primary North American resource for anaemia education and research
    A R Nissenson
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, and The National Anaemia Action Council, Inc, Milwaukee, Wisconsin, USA
    Eur J Clin Invest 35:100-6. 2005
  7. ncbi Influence of industry on renal guideline development commentary: keeping our eye on the ball and improving chronic kidney disease patient outcomes
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Clin J Am Soc Nephrol 2:205-6. 2007
  8. ncbi Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease
    A R Nissenson
    Department of Medicine, and Division of Nephrology, University of California, Los Angeles, School of Medicine, and UCLA Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 38:1390-7. 2001
  9. ncbi Improving outcomes in CKD and ESRD patients: carrying the torch from training to practice
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Semin Dial 17:380-97. 2004
  10. ncbi Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns
    A R Nissenson
    Department of Medicine, University of California Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    J Am Soc Nephrol 12:1713-20. 2001

Detail Information

Publications70

  1. ncbi The human nephron filter: toward a continuously functioning, implantable artificial nephron system
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Blood Purif 23:269-74. 2005
    ..The enhanced solute removal and wearable design should substantially improve patient outcomes and quality of life...
  2. ncbi Continuously functioning artificial nephron system: the promise of nanotechnology
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, California 90095, USA
    Hemodial Int 9:210-7. 2005
    ..The enhanced solute removal and wearable design should substantially improve patient outcomes and quality of life...
  3. ncbi Restructuring the ESRD payment system in the United States
    Allen R Nissenson
    David Geffen School of Medicine and UCLA Medical Center, Los Angeles, California, USA
    Kidney Int 66:466-76. 2004
  4. ncbi Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients
    Allen R Nissenson
    University of California at Los Angeles Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 40:110-8. 2002
    ..The purpose of this randomized, double-blind, noninferiority study is to determine whether darbepoetin alfa is as effective as epoetin for the treatment of anemia in hemodialysis patients when administered at a reduced dosing frequency...
  5. ncbi Septicemia in patients with ESRD is associated with decreased hematocrit and increased use of erythropoietin
    Allen R Nissenson
    David Geffen School of Medicine, University of California Los Angeles, 200 UCLA Medical Plaza, Suite 565 57, Los Angeles, CA 90095, USA
    Clin J Am Soc Nephrol 1:505-10. 2006
    ..Strategies to prevent septicemia are important not only to decrease clinical morbidity but also to conserve EPO usage and thus contain the costs of care for this complex patient population...
  6. ncbi The National Anaemia Action Council, Inc.: the primary North American resource for anaemia education and research
    A R Nissenson
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, and The National Anaemia Action Council, Inc, Milwaukee, Wisconsin, USA
    Eur J Clin Invest 35:100-6. 2005
    ..This editorial illustrates the goals and objectives of NAAC, and depicts past, present and future educational and research projects and findings. NAAC resources in anaemia-related education and research are described in detail...
  7. ncbi Influence of industry on renal guideline development commentary: keeping our eye on the ball and improving chronic kidney disease patient outcomes
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Clin J Am Soc Nephrol 2:205-6. 2007
  8. ncbi Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease
    A R Nissenson
    Department of Medicine, and Division of Nephrology, University of California, Los Angeles, School of Medicine, and UCLA Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 38:1390-7. 2001
    ..There have been no reports of antibody formation associated with NESP. NESP is an important new tool for physicians to use in the treatment of anemia of chronic kidney disease...
  9. ncbi Improving outcomes in CKD and ESRD patients: carrying the torch from training to practice
    Allen R Nissenson
    Department of Medicine, Division of Nephrology, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Semin Dial 17:380-97. 2004
    ..If nephrologists are to take their appropriate place as leaders of the care delivery team, nephrology fellowships must be restructured with appropriate emphasis placed on the comprehensive care of ESRD and CKD patients...
  10. ncbi Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns
    A R Nissenson
    Department of Medicine, University of California Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    J Am Soc Nephrol 12:1713-20. 2001
    ..Providers, policy-makers, and payers should view CKD as a major public health problem and initiate innovative programs to address this growing patient population...
  11. ncbi Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization
    A R Nissenson
    University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
    Am J Kidney Dis 37:1177-83. 2001
    ..The time has come for a structured public and professional educational program to address this serious condition...
  12. ncbi Evaluation of disease-state management of dialysis patients
    A R Nissenson
    University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
    Am J Kidney Dis 37:938-44. 2001
    ....
  13. ncbi Economic burden of anemia in an insured population
    Allen R Nissenson
    Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, 90095 6945, USA
    J Manag Care Pharm 11:565-74. 2005
    ..This study examines anemia prevalence and associated medical costs and utilization, using administrative claims for adults newly diagnosed with anemia, including up to 12 months of follow-up...
  14. ncbi Anemia: not just an innocent bystander?
    Allen R Nissenson
    Arch Intern Med 163:1400-4. 2003
  15. ncbi What common practices in dialysis units can be altered to improve patient care?
    Allen R Nissenson
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Semin Dial 17:12-3. 2004
  16. ncbi Bottom-up nanotechnology: the human nephron filter
    Allen R Nissenson
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Semin Dial 22:661-4. 2009
    ..The enhanced solute removal and wearable design should substantially improve patient outcomes and quality of life...
  17. ncbi Associations of pretransplant serum albumin with post-transplant outcomes in kidney transplant recipients
    M Z Molnar
    Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Am J Transplant 11:1006-15. 2011
    ..Clinical trials to examine interventions to improve nutritional status in transplant-waitlisted hemodialysis patients and their impacts on post-transplant outcomes are indicated...
  18. ncbi Achieving target hematocrit in dialysis patients: new concepts in iron management
    A R Nissenson
    Department of Medicine, UCLA School of Medicine, USA
    Am J Kidney Dis 30:907-11. 1997
    ....
  19. ncbi Optimal hematocrit in patients on dialysis therapy
    A R Nissenson
    Department of Medicine, University of California at Los Angeles, USA
    Am J Kidney Dis 32:S142-6. 1998
    ....
  20. ncbi Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study
    Brigitte Schiller
    Satellite Healthcare Inc, Mountain View, California, USA
    Hemodial Int 12:441-9. 2008
    ..The patient questionnaire reported insufficient education on CKD. Use of a once-monthly ESA to correct anemia in dialysis patients may provide substantial time, resource, and cost savings compared with current treatment practices...
  21. ncbi Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial
    A R Nissenson
    University of California at Los Angeles Medical Center, 90095, USA
    Am J Kidney Dis 33:471-82. 1999
    ..0 g to achieve optimal response in hemoglobin and hematocrit levels...
  22. ncbi Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients
    Allen R Nissenson
    University of California, Los Angeles, CA, USA
    Am J Kidney Dis 42:325-30. 2003
    ..This treatment was associated with a significant increase in rHuEPO efficiency (P = 0.04)...
  23. ncbi Iron deficiency in patients with renal failure
    A R Nissenson
    Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Kidney Int Suppl 69:S18-21. 1999
    ..It is essential, therefore, for renal health professionals to understand iron metabolism in dialysis patients in order to properly balance the therapy of renal anemia with rHuEPO and supplemental iron...
  24. ncbi Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States
    Rajiv Agarwal
    Division of Nephrology, Department of Medicine, Indiana University School of Medicine, and RLR VA Medical Center, Indianapolis 46202, USA
    Am J Med 115:291-7. 2003
    ..Hypertension is common in chronic hemodialysis patients, yet there are limited data on the epidemiology of hypertension in these patients in the United States...
  25. ncbi The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?
    S Fishbane
    Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
    Kidney Int 72:806-13. 2007
    ..In this review, we consider the recent literature, the change in FDA warnings, and new National Kidney Foundation Anemia Guidelines. Suggestions for new Hb targets during erythropoiesis-stimulating agent treatment are presented...
  26. ncbi Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kamyar Kalantar-Zadeh
    Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Adv Chronic Kidney Dis 16:143-51. 2009
    ....
  27. ncbi Renal replacement therapy in the elderly
    Xiaoyi Ye
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Room 7 155 Factor Building, Los Angeles, CA 90095, USA
    Clin Geriatr Med 25:529-42. 2009
    ..As the United States population ages, physicians will have to face many challenges associated with aging, whether medical, psychosocial, or ethical. This article discusses issues specific to the geriatric dialysis population...
  28. ncbi The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis
    Kamyar Kalantar-Zadeh
    Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    Mayo Clin Proc 85:991-1001. 2010
    ..To determine whether dry weight gain accompanied by an increase in muscle mass is associated with a survival benefit in patients receiving maintenance hemodialysis (HD)...
  29. ncbi Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients
    Nazanin Noori
    Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Clin J Am Soc Nephrol 5:2258-68. 2010
    ..We hypothesized that mid-arm muscle circumference (MAMC), a conveniently measured surrogate of lean body mass (LBM), has stronger association with clinical outcomes than triceps skinfold (TSF), a surrogate of fat mass...
  30. ncbi Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients
    Kamyar Kalantar-Zadeh
    Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA, USA
    J Bone Miner Res 25:2724-34. 2010
    ..Survival advantages of blacks appear restricted to those receiving higher doses of active vitamin D. Examining the effect of MBD modulation on racial survival disparities of hemodialysis patients is warranted...
  31. ncbi Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease
    Kamyar Kalantar-Zadeh
    Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, C1 Annex, Torrance, CA 90509 2910, USA
    Clin J Am Soc Nephrol 5:519-30. 2010
    ..Provision of in-center and monitored meals during hemodialysis treatment sessions in the dialysis clinic may facilitate the achievement of these goals...
  32. ncbi Technological advances in renal replacement therapy: five years and beyond
    Anjay Rastogi
    Department of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin J Am Soc Nephrol 4:S132-6. 2009
    ..In summary, nephrology is at an exciting crossroad with the application of innovative and novel technologies to RRT that hold considerable promise for the near future...
  33. ncbi Disease management in chronic kidney disease
    Anjay Rastogi
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1689, USA
    Adv Chronic Kidney Dis 15:19-28. 2008
    ..Recent experience suggests that these barriers can be overcome, with DM becoming a promising approach for improving outcomes for this vulnerable population...
  34. ncbi Hepcidin--a potential novel biomarker for iron status in chronic kidney disease
    Joshua Zaritsky
    Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Clin J Am Soc Nephrol 4:1051-6. 2009
    ..Hepcidin is a key regulator of iron homeostasis, but its study in the setting of chronic kidney disease (CKD) has been hampered by the lack of validated serum assays...
  35. ncbi High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine
    O Kenrik Duru
    Division of General Internal Medicine, University of California, Los Angeles, CA 90095, USA
    J Gen Intern Med 24:86-92. 2009
    ..Serum creatinine is commonly used to diagnose chronic kidney disease (CKD), but may underestimate CKD in older adults when compared with using glomerular filtration rates (eGFR). The magnitude of this underestimation is not clearly defined...
  36. ncbi Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Harbor UCLA Medical Center, Harbor Mailbox 406, 1000 West Carson St, Torrance, CA 90509 2910, USA
    Am J Kidney Dis 42:761-73. 2003
    ..Elements of malnutrition-inflammation complex syndrome (MICS) may blunt the responsiveness of anemia of end-stage renal disease (ESRD) to recombinant human erythropoietin (EPO)...
  37. ncbi Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis
    Allen R Nissenson
    David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Am J Kidney Dis 46:301-8. 2005
    ..CONCLUSION: Patients with septicemia caused by S aureus had costly and lengthy hospitalizations, which frequently were associated with clinically and economically important complications, including hospital readmissions...
  38. ncbi Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients
    M Z Molnar
    Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Am J Transplant 11:725-36. 2011
    ..Transplant-waitlisted hemodialysis patients with lower BMI or muscle mass and/or unintentional weight or muscle loss have higher mortality in this observational study. Impact of intentional weight change remains unclear...
  39. ncbi Daily hemodialysis: challenges and opportunities in the delivery and financing of end-stage renal disease patient care
    A R Nissenson
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    Adv Ren Replace Ther 8:286-92. 2001
    ....
  40. ncbi Erythropoietin and anemia
    E M Tong
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    Semin Nephrol 21:190-203. 2001
    ....
  41. ncbi The future of renal replacement therapy
    Anjay Rastogi
    UCLA Medical Center, Los Angeles, CA 90095, USA
    Adv Chronic Kidney Dis 14:249-55. 2007
    ..In summary, nephrology is at an exciting crossroad with the application of innovative and novel technologies to RRT that hold considerable promise for the near future...
  42. ncbi Epoetin-associated pure red cell aplasia: past, present, and future considerations
    June M McKoy
    Division of Hematology Oncology and Geriatric Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Transfusion 48:1754-62. 2008
    ..In 1998, epoetin-associated pure red cell aplasia (PRCA) was first reported and causation was attributed to formulations without human serum albumin (HSA), subcutaneous administration, and uncoated rubber stoppers...
  43. ncbi Chronic kidney disease in the United States: a public policy imperative
    Richard A Rettig
    RAND Corporation, Santa Monica, California, USA
    Clin J Am Soc Nephrol 3:1902-10. 2008
    ..In 2003, the Council of American Kidney Societies (CAKS) identified 19 barriers to improved patient outcomes in chronic kidney disease (CKD)...
  44. ncbi Emphasizing patient choice: the modality selection project in ESRD Network 18
    Rajnish Mehrotra
    Division of Nephrology, Research and Education Institute, Harbor-UCLA Medical Center, School of Medicine, USA
    Nephrol News Issues 17:30-6. 2003
    ..This in turn, would lead to better preparation of patients for RRT and hopefully, have a positive impact on the morbidity and mortality of maintenance dialysis patients...
  45. ncbi Dialysis in nursing homes
    Eric M Tong
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Semin Dial 15:103-6. 2002
    ..Although another approach could be to more fully utilize the services of adult day care centers, this has proven logistically difficult and has not been reported to be successful since it was first suggested more than a decade ago...
  46. ncbi The case for disease management in chronic kidney disease
    Randolph A Chen
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Dis Manag 9:86-92. 2006
    ..Considering the magnitude of the opportunity, DM applied to CKD is a promising approach to the care of this vulnerable population...
  47. ncbi Disease management improves outcomes in patients with CKD
    Allen R Nissenson
    Dialysis Program, David Geffen School of Medicine, Department of Medicine, Division of Nephrology, UCLA Medical Center, Los Angeles, Calif, USA
    Nephrol News Issues 17:15-9. 2003
  48. ncbi Dialysis outcomes as a measure of adequacy of dialysis
    Michael Butman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, USA
    Semin Nephrol 25:70-5. 2005
    ..Optimal dialysis will be accomplished only when normal kidney functions are mimicked by artificial devices to a much greater extent than is currently the case...
  49. ncbi Determinants in APD selection
    Jimmy Wilson
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Semin Dial 15:388-92. 2002
    ....
  50. ncbi Race, gender, and socioeconomic disparities in CKD in the United States
    Keith Norris
    Charles Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA 90059, USA
    J Am Soc Nephrol 19:1261-70. 2008
    ..By so doing, we could become global leaders not only in medical technology, as we currently are, but also in health promotion and disease prevention, truly leaving no patient behind...
  51. ncbi Vascular access for hemodialysis
    Rick Hayashi
    UCLA Medical Center, Los Angeles, CA, USA
    Nat Clin Pract Nephrol 2:504-13. 2006
    ..This paper reviews the 2000 K/DOQI dialysis access guideline as well as updated information published subsequently...
  52. ncbi Utilizing a disease management approach to improve ESRD patient outcomes
    Shaan Anand
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Semin Dial 15:38-40. 2002
    ..Early data suggest a disease management approach may improve both the morbidity and mortality of CKD patients...
  53. ncbi Role of sodium and volume in the pathogenesis of hypertension in hemodialysis
    Jimmy Wilson
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Semin Dial 17:260-4. 2004
    ..Aggressive control of extracellular volume and dietary sodium intake can normalize BP in chronic HD patients and reduce the morbidity associated with hypertension-related CV disease...
  54. ncbi Epoetin dosing and dialysis facility ownership
    Alan S Kliger
    JAMA 298:861-2; author reply 862-3. 2007
  55. ncbi Mortality differences among organisms causing septicemia in hemodialysis patients
    Mark D Danese
    Outcomes Insights Inc, Newbury Park, California 91320, USA
    Hemodial Int 10:56-62. 2006
    ..Meningitis, stroke, and endocarditis represent particularly serious complications. Overall, septicemia hospitalizations (especially for S. aureus) are serious events, and patients would benefit from better treatment and prevention...
  56. ncbi Dosing darbepoetin alfa
    Allen R Nissenson
    Am J Kidney Dis 40:872. 2002
  57. ncbi Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran
    Beckie Michael
    Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Kidney Int 61:1830-9. 2002
    ..S. under FDA's priority drug review. This Phase IV study was designed to evaluate the safety of a single dose of intravenous SFGC as compared to placebo and a historical iron dextran control...
  58. ncbi Pure red-cell aplasia and epoetin therapy
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
    N Engl J Med 351:1403-8. 2004
    ....
  59. ncbi Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment
    Steven Fishbane
    Semin Dial 17:336-41. 2004
    ..Clinical judgment is critical to properly weigh the risks and benefits of intravenous iron treatment in the context of the individual patient...
  60. ncbi Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients
    Daniel W Coyne
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Kidney Int 63:217-24. 2003
    ....
  61. ncbi L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they?
    Theodore I Steinman
    Nephrol News Issues 17:28-30, 32-4, 36 passim. 2003
    ..Until there is scientific evidence to support use of L-carnitine supplementation, and it proves to be cost-effective, reimbursement is not justified. Therefore, the current CMS reimbursement decision for L-carnitine appears to be flawed...
  62. ncbi Anemia and its clinical consequences in patients with chronic diseases
    Lawrence Tim Goodnough
    Division of Laboratory Medicine, Washington University Medical Center, St. Louis, Missouri 63130, USA
    Am J Med 116:1S-2S. 2004
  63. ncbi Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis
    Elani Streja
    Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    Am J Kidney Dis 52:727-36. 2008
    ..High doses of human recombinant erythropoietin (rHuEPO) to achieve hemoglobin levels greater than 13 g/dL in patients with chronic kidney disease appear to be associated with increased mortality...
  64. ncbi Economics of clinical nephrology practice
    Robert Provenzano
    Department of Nephrology, St. John Hospital and Medical Center, Detroit, MI 48230, USA
    Am J Kidney Dis 44:168-78. 2004
  65. ncbi Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature
    Alisa Wilson
    Zynx Health, Beverly Hills, California 90212, USA
    Am J Med 116:50S-57S. 2004
    ..Whether improvements in QOL and/or joint symptoms occur with improvement of anemia, independent of other signs of an overall response to RA therapy, remains to be determined...
  66. ncbi The normal hematocrit study--follow-up
    Anatole Besarab
    N Engl J Med 358:433-4. 2008
  67. ncbi Identification, diagnosis, and management of anemia in adult ambulatory patients treated by primary care physicians: evidence-based and consensus recommendations
    Robert W Dubois
    Cerner Health Insights, Beverly Hills, CA 90212, USA
    Curr Med Res Opin 22:385-95. 2006
    ..Provide recommendations for the identification, diagnosis, and management of ambulatory patients with anemia...
  68. ncbi Pure red-cell aplasia: an emerging epidemic in dialysis patients?
    Shaan Anand
    Perit Dial Int 23:317-9. 2003
  69. ncbi The chronic kidney disease initiative
    Thomas F Parker
    Dallas Nephrology Associates, University of Texas Southwestern Medical School, Dallas, TX 75235, USA
    J Am Soc Nephrol 15:708-16. 2004
    ..This article describes the process, the barriers encountered, and the solutions required to fully identify and manage this large and complicated population of patients...
  70. ncbi Racial differences in mortality and ESRD
    Keith Norris
    Am J Kidney Dis 52:205-8. 2008